Vantage Financial Partners Ltd. Inc. grew its position in shares of Allergan plc (NYSE:AGN) by 23.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,250 shares of the company’s stock after purchasing an additional 1,200 shares during the period. Allergan comprises about 0.7% of Vantage Financial Partners Ltd. Inc.’s holdings, making the stock its 22nd largest holding. Vantage Financial Partners Ltd. Inc.’s holdings in Allergan were worth $1,018,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of AGN. Edgewood Management LLC increased its holdings in Allergan by 24.3% during the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares during the period. Baupost Group LLC MA increased its holdings in Allergan by 21.9% during the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after purchasing an additional 531,600 shares during the period. Parnassus Investments CA increased its holdings in Allergan by 20.4% during the 4th quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock valued at $353,633,000 after purchasing an additional 365,914 shares during the period. Epoch Investment Partners Inc. increased its holdings in Allergan by 1.0% during the 3rd quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after purchasing an additional 17,068 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in Allergan by 13.6% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,763,209 shares of the company’s stock valued at $288,426,000 after purchasing an additional 210,962 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.
In other Allergan news, CEO Brent L. Saunders purchased 3,300 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was acquired at an average price of $152.53 per share, for a total transaction of $503,349.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Matthew M. Walsh purchased 1,000 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was acquired at an average price of $153.96 per share, with a total value of $153,960.00. The disclosure for this purchase can be found here. Insiders acquired a total of 7,200 shares of company stock valued at $1,108,267 in the last quarter. 0.36% of the stock is currently owned by company insiders.
Allergan plc (NYSE AGN) traded up $3.87 during trading hours on Wednesday, hitting $167.06. The stock had a trading volume of 5,080,000 shares, compared to its average volume of 3,900,000. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 1.06. The stock has a market cap of $56,850.00, a price-to-earnings ratio of -13.93, a price-to-earnings-growth ratio of 1.12 and a beta of 1.29. Allergan plc has a 52-week low of $142.81 and a 52-week high of $256.80.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The business had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. During the same quarter in the prior year, the business posted $3.90 EPS. Allergan’s revenue for the quarter was up 12.0% compared to the same quarter last year. research analysts anticipate that Allergan plc will post 15.58 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.72%. The ex-dividend date is Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is presently -24.02%.
ILLEGAL ACTIVITY WARNING: This report was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2018/03/14/allergan-plc-agn-position-increased-by-vantage-financial-partners-ltd-inc.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.